Hence, it is essential to critically assess whether galectins-1 and -3 can overcome remyelination failure in a MS lesion environment, and to verify whether a specific galectin-4 antagonist such as a high-affinity sulfatide derivative or a neutralizing antibody against galectin-4 counteracts its inhibiting effect on OPC differentiation. This evidence concerns the gene LGALS4 and myeloid sarcoma.